19/04/2024 - General information
He is one of the four runner-ups awarded. He won it for his research in the field of neuroscience and cannabinoid drugs. Dr. Arnau Busquets, coordinator of the Cellular Mechanisms in Physiological and Pathological Behavior Research Group at the Hospital del Mar Research Institute, has won one of the runner-up awards at the 60th Anniversary Farmaindustria Young Researchers Prize. The winner of the prize was Cristina Mayor-Ruiz, from the Biomedical Research Institute of Barcelona. The awards were presented on April 18 at the Círculo de Bellas Artes in Madrid.
15/04/2024 - General information
The Reial Acadèmia de Medicina de Catalunya chose, in a plenary session held on April 9, Dr. Manuel Pera as the new full academician of the institution. Dr. Pera, who was already a corresponding academic since 2022, will be attached to the surgery section of the institution. The section chief of the Gastrointestinal Surgery Unit of the Hospital del Mar and researcher at the center's Research Institute, thus becomes one of the sixty full academicians of the institution. The election is made by a vote among the members themselves. The ceremony of entry into the Royal Academy will take place in the coming months.
20/02/2024 - General information
He does so as a Reference Researcher, the highest possible category. A fact that recognizes his research activity in recent years. Dr. Daniel Guinart, consultant psychiatrist at the Psychosocial Rehabilitation and Treatment-Resistant Schizophrenia Unit of the Hospital del Mar and researcher at its research institute, has achieved the category of Reference Researcher of the Sociedad Española de Psiquiatría y Salud Mental (SEPSM). This recognition of his work is part of the Research Excellence Program of the organization.
19/02/2024 - General information
The Ministry of Science, Innovation and Universities and the European Union, through the Next Generation EU program will finance this new phase. It will evaluate the efficacy of CTH120 as an innovative therapy in adult patients with SXF, the most common form of hereditary intellectual disability without specific treatment. The public-private consortium formed by the biotechnology company CONNECTA Therapeutics, the Hospital del Mar Research Institute, the Center for Genomic Regulation (CRG), and the Parc Taulí Research and Innovation Institute (I3PT) will receive 2,7 million euros in funding from the Ministry of Science, Innovation and Universities and the European Union, through the Next Generation EU program, to initiate Phase IIa clinical trials of the drug CTH120 for the treatment of Fragile X syndrome (Fragile X syndrome).
Més informació "Nearly 3 million euros to initiate Phase IIa of CTH120 drug for Fragile X syndrome"
06/02/2024 - General information
Sociodemographic, epidemiological, technological and societal demand changes make it necessary to face a transformation of the health system in order to promote both its own sustainability and the improvement of expected health outcomes. In order to carry out this transformation, long term strategies are needed, which go beyond the cycles of government, as well as the commitment between the different agents that have influence there. For this reason, it is considered necessary to do so through a National Health Pact.
Més informació "Citizen Participation Process in the National Health Pact"
26/01/2024 - General information
Drs. Anna Bigas and David Sprinzak from Tel Aviv University have published comprehensive reviews as editors on the mechanisms of cell communication in various tissues. This review is a potential study to understand how life and diseases develop.
Més informació "Local Cellular Interactions Analyzed in Current Opinion in Cell Biology"
19/01/2024 - General information
The Minister of Health officially announced the cardiologist's appointment from Hospital del Mar and researcher at the Hospital del Mar Research Institute last December. Dr. Tizón replaces Dr. Josepa Mauri from Hospital Germans Trias i Pujol, who held this position for the past 8 years.
People with HIV have altered levels of a specific RNA molecule related to both aging and inflammation. This molecule remains altered even with antiretroviral treatment, indicating that their immune system remains affected despite receiving antiretroviral treatment and controlling the infection. The authors of the study, published in the Journal of Microbiology, Immunology, and Infection, suggest that the origin of this alteration is chronic inflammation caused by the infection, regardless of the treatment received by patients. Having this marker can be helpful in monitoring the evolution of patients and the effectiveness of the drugs they take to restore the normal functioning of their immune system.
24/11/2023 - General information
33 new research projects received funding of up to 500,000 euros or up to one million euros in the sixth edition of the CaixaResearch Health Research call, promoted by the "la Caixa" Foundation. In total, 25.3 million euros in grants. The call supports basic, clinical, or translational research projects with scientific excellence and social impact in cardiovascular diseases, infections, oncology, and neurosciences. It also supports projects developing enabling technologies in these areas. Among the selected projects is one led by Dr. Toni Celià-Terrassa to advance the understanding of metastasis and its coevolution with the immune system. There are also two other projects with the participation of researchers from the Hospital del Mar, Dr. Víctor Pérez, and Dr. Arnau Busquets.
The Lancet Public Health journal has published the results of one of the largest and most up-to-date studies worldwide to evaluate the point prevalence of clinically relevant depressive symptoms.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
